Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.

Literature DB >> 27995082

Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.

M Kudo¹.
1. Editor Liver Cancer.

Abstract

Entities: Disease

Year: 2016 PMID： 27995082 PMCID： PMC5159737 DOI： 10.1159/000449342

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

38 in total

1. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal: Nature Date: 2014-11-27 Impact factor: 49.962

Review 3. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors: Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal: Curr Opin Immunol Date: 2012-01-09 Impact factor: 7.486

Review 4. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Authors: George K Philips; Michael Atkins
Journal: Int Immunol Date: 2014-10-16 Impact factor: 4.823

5. Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Authors: Lauren C Harshman; Charles G Drake; Jennifer A Wargo; Padmanee Sharma; Nina Bhardwaj
Journal: Cancer Immunol Res Date: 2014-08 Impact factor: 11.151

6. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors: Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531

Review 7. Image-Guided Ablation of Malignant Liver Tumors: Recommendations for Clinical Validation of Novel Thermal and Non-Thermal Technologies - A Western Perspective.

Authors: Riccardo Lencioni; Thierry de Baere; Robert C Martin; Charles W Nutting; Govindarajan Narayanan
Journal: Liver Cancer Date: 2015-10-21 Impact factor: 11.740

8. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

9. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors: Y Ishida; Y Agata; K Shibahara; T Honjo
Journal: EMBO J Date: 1992-11 Impact factor: 11.598

10. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors: M F Krummel; J P Allison
Journal: J Exp Med Date: 1995-08-01 Impact factor: 14.307

23 in total

Review 1. Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.

Authors: Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal: Eur Radiol Date: 2019-04-08 Impact factor: 5.315

Review 2. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors: Rohit Loomba; T Jake Liang
Journal: Gastroenterology Date: 2017-02-20 Impact factor: 22.682

3. Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2019-04-29 Impact factor: 11.740

4. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2018-08-23 Impact factor: 11.740

Review 5. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors: Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal: J Clin Exp Hepatol Date: 2019-01-25

6. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2019-07-09 Impact factor: 11.740

7. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2020-03-05 Impact factor: 11.740

8. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.

Authors: Daniel J McGrail; Parnit K Bhupal; Junying Wang; Wen Zhang; Kuan-Yu Lin; Yi-Hsuan Ku; Tao Lin; Hongfu Wu; Kyle C Tsai; Kaiyi Li; Cheng-Yuan Peng; Milton J Finegold; Shiaw-Yih Lin; Robert Y L Tsai
Journal: Mol Cancer Res Date: 2020-02-12 Impact factor: 5.852

Review 9. Challenges in liver cancer and possible treatment approaches.

Authors: David Anwanwan; Santosh Kumar Singh; Shriti Singh; Varma Saikam; Rajesh Singh
Journal: Biochim Biophys Acta Rev Cancer Date: 2019-11-01 Impact factor: 10.680

Review 10. Immunomodulation in hepatocellular cancer.

Authors: Sunyoung Lee; Matthew Loecher; Renuka Iyer
Journal: J Gastrointest Oncol Date: 2018-02